Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US

In This Article:

Over the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name

PE

PS

Discount to Fair Value

Value Rating

Capital Bancorp

14.1x

2.9x

48.35%

★★★★☆☆

Franklin Financial Services

10.5x

2.1x

31.63%

★★★★☆☆

HighPeak Energy

11.4x

1.6x

33.33%

★★★★☆☆

Pebblebrook Hotel Trust

NA

1.0x

12.62%

★★★★☆☆

German American Bancorp

16.3x

5.4x

43.76%

★★★☆☆☆

USCB Financial Holdings

18.9x

5.4x

48.98%

★★★☆☆☆

First United

13.8x

3.1x

46.34%

★★★☆☆☆

Orion Group Holdings

NA

0.4x

-235.34%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Tilray Brands

NA

1.5x

-76.94%

★★★☆☆☆

Click here to see the full list of 39 stocks from our Undervalued US Small Caps With Insider Buying screener.

Let's uncover some gems from our specialized screener.

ACNB

Simply Wall St Value Rating: ★★★☆☆☆

Overview: ACNB is a financial services company primarily engaged in banking and insurance operations, with a market capitalization of $0.29 billion.

Operations: The company's primary revenue streams are from its banking and insurance segments, with banking contributing significantly more. Operating expenses are a major cost component, consistently exceeding $60 million in recent periods. The net income margin has shown variability, reaching as high as 34.31% in June 2023 before declining to 27.58% by September 2024.

PE: 13.7x

ACNB Corporation, a smaller company by market capitalization, has recently shown insider confidence with share purchases. Despite a decrease in net income to US$7.2 million for Q3 2024 from US$9.04 million the previous year, the company maintains its appeal through strategic buybacks and dividend growth, increasing its quarterly dividend by 6.7% to US$0.32 per share. Looking ahead, earnings are projected to grow at an annual rate of 18.75%, suggesting potential for future value appreciation despite current challenges.

NasdaqCM:ACNB Share price vs Value as at Nov 2024
NasdaqCM:ACNB Share price vs Value as at Nov 2024

Maravai LifeSciences Holdings

Simply Wall St Value Rating: ★★★★★☆

Overview: Maravai LifeSciences Holdings specializes in providing products and services for nucleic acid production and biologics safety testing, with a market capitalization of $1.88 billion.

Operations: Nucleic Acid Production is the primary revenue stream, generating $213.27 million, followed by Biologics Safety Testing at $63.65 million. The company has experienced fluctuations in its net income margin, with recent periods showing a decline to -81.13%. Gross profit margin also saw a decrease from 83.33% in early 2022 to 46.36% by late 2024.

Waiting for permission
Allow microphone access to enable voice search

Try again.